Skip to main content
Erschienen in: Journal of Thrombosis and Thrombolysis 2/2016

14.03.2016

Review of venous thromboembolism and race: the generalizability of treatment guidelines for high-risk populations

verfasst von: Lonnie T. Sullivan II, Larry R. Jackson II, Kevin L. Thomas

Erschienen in: Journal of Thrombosis and Thrombolysis | Ausgabe 2/2016

Einloggen, um Zugang zu erhalten

Abstract

The American College of Chest Physicians (ACCP) has established guidelines for the treatment of VTE, but the generalizability to all populations is unclear. In this review we analyzed the rate of reporting and enrollment of blacks and women in clinical trials cited in the ACCP guidelines for treatment of unprovoked VTE. We extracted data from clinical trials cited by the ACCP that compared durations of anticoagulation therapy for the treatment of unprovoked VTE. We excluded trials that treated surgical or cancer patients. For trials that did not report race/ethnicity we contacted the primary investigators via email for enrollment data. The final analysis included 17 randomized clinical trials with a total patient population of N = 13,693. All trials reported data on sex; conversely, 2 trials (11.8 %) reported race/ethnicity within the primary manuscript. We ultimately acquired data on race/ethnicity from the primary investigator in 5 additional trials for a total race/ethnicity data from 7 trials. There were 7573 males (55.3 %) and 6120 females (44.7 %) enrolled in these studies. Among trials that reported race and ethnicity the total patient population was N = 5368; 5171 (96.3 %) white, 115 (2.1 %) black, 65 (1.4 %) Asian and 7 (0.25 %) Hispanic. Racial/ethnic minorities are underreported and under represented in clinical trials forming the cornerstone of ACCP guidelines for the optimal duration for VTE treatment. Conversely, the reporting and inclusion of women was substantive. The guidelines for unprovoked VTE treatment may not be generalizable to racially and ethnically diverse patient populations.
Literatur
1.
Zurück zum Zitat Rosendaal FR, Raskob GE (2014) On world thrombosis day. Lancet 384(9955):1653–1654CrossRef Rosendaal FR, Raskob GE (2014) On world thrombosis day. Lancet 384(9955):1653–1654CrossRef
2.
Zurück zum Zitat Naess IA, Christiansen SC, Romundstad P, Cannegieter SC, Rosendaal FR, Hammerstrøm J (2007) Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost 5(4):692–699CrossRefPubMed Naess IA, Christiansen SC, Romundstad P, Cannegieter SC, Rosendaal FR, Hammerstrøm J (2007) Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost 5(4):692–699CrossRefPubMed
3.
Zurück zum Zitat Beckman MG, Hooper WC, Critchley SE, Ortel TL (2010) Venous thromboembolism: a public health concern. Am J Prev Med 38(4):S495–S501CrossRefPubMed Beckman MG, Hooper WC, Critchley SE, Ortel TL (2010) Venous thromboembolism: a public health concern. Am J Prev Med 38(4):S495–S501CrossRefPubMed
4.
Zurück zum Zitat Zakai NA, McClure LA (2011) Racial differences in venous thromboembolism. J Thromb Haemost 9(10):1877–1882CrossRefPubMed Zakai NA, McClure LA (2011) Racial differences in venous thromboembolism. J Thromb Haemost 9(10):1877–1882CrossRefPubMed
5.
Zurück zum Zitat White RH, Zhou H, Murin S, Harvey D (2005) Effect of ethnicity and gender on the incidence of venous thromboembolism in a diverse population in California in 1996. Thromb Haemost 93(2):298–305PubMed White RH, Zhou H, Murin S, Harvey D (2005) Effect of ethnicity and gender on the incidence of venous thromboembolism in a diverse population in California in 1996. Thromb Haemost 93(2):298–305PubMed
6.
Zurück zum Zitat White RH, Keenan CR (2009) Effects of race and ethnicity on the incidence of venous thromboembolism. Thromb Res 123:S11–S17CrossRefPubMed White RH, Keenan CR (2009) Effects of race and ethnicity on the incidence of venous thromboembolism. Thromb Res 123:S11–S17CrossRefPubMed
8.
Zurück zum Zitat Aujesky D, Long JA, Fine MJ, Ibrahim SA (2007) African American race was associated with an increased risk of complications following venous thromboembolism. J Clin Epidemiol 60(4):410–416CrossRefPubMed Aujesky D, Long JA, Fine MJ, Ibrahim SA (2007) African American race was associated with an increased risk of complications following venous thromboembolism. J Clin Epidemiol 60(4):410–416CrossRefPubMed
9.
Zurück zum Zitat Deitelzweig SB, Lin J, Johnson BH, Schulman KL (2011) Venous thromboembolism in the US: does race matter? J Thromb Thrombolysis 31(2):133–138CrossRefPubMed Deitelzweig SB, Lin J, Johnson BH, Schulman KL (2011) Venous thromboembolism in the US: does race matter? J Thromb Thrombolysis 31(2):133–138CrossRefPubMed
10.
Zurück zum Zitat White RH, Dager WE, Zhou H, Murin S (2006) Racial and gender differences in the incidence of recurrent venous thromboembolism. Thromb Haemost-Stuttg 96(3):267 White RH, Dager WE, Zhou H, Murin S (2006) Racial and gender differences in the incidence of recurrent venous thromboembolism. Thromb Haemost-Stuttg 96(3):267
11.
Zurück zum Zitat Liu J, Hickson DA, Musani SK, Talegawkar SA, Carithers TC, Tucker KL, Taylor HA (2013) Dietary patterns, abdominal visceral adipose tissue, and cardiometabolic risk factors in African Americans: the Jackson heart study. Obesity 21(3):644–651CrossRefPubMedPubMedCentral Liu J, Hickson DA, Musani SK, Talegawkar SA, Carithers TC, Tucker KL, Taylor HA (2013) Dietary patterns, abdominal visceral adipose tissue, and cardiometabolic risk factors in African Americans: the Jackson heart study. Obesity 21(3):644–651CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Austin H, Key NS, Benson JM, Lally C, Dowling NF, Whitsett C, Hooper WC (2007) Sickle cell trait and the risk of venous thromboembolism among blacks. Blood 110(3):908–912CrossRefPubMed Austin H, Key NS, Benson JM, Lally C, Dowling NF, Whitsett C, Hooper WC (2007) Sickle cell trait and the risk of venous thromboembolism among blacks. Blood 110(3):908–912CrossRefPubMed
13.
Zurück zum Zitat Payne AB, Miller CH, Hooper WC, Lally C, Austin HD (2014) High factor VIII, von Willebrand factor, and fibrinogen levels and risk of venous thromboembolism in blacks and whites. Risk 24(2):169–174 Payne AB, Miller CH, Hooper WC, Lally C, Austin HD (2014) High factor VIII, von Willebrand factor, and fibrinogen levels and risk of venous thromboembolism in blacks and whites. Risk 24(2):169–174
14.
Zurück zum Zitat Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ, Kahn SR (2012) Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians evidence-based clinical practice guidelines. Chest J 141(2_suppl):e419S–e494SCrossRef Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ, Kahn SR (2012) Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians evidence-based clinical practice guidelines. Chest J 141(2_suppl):e419S–e494SCrossRef
15.
Zurück zum Zitat Lagerstedt C, Fagher B, Olsson CG, Öqvist B, Albrechtsson U (1985) Need for long-term anticoagulant treatment in symptomatic calf-vein thrombosis. Lancet 326(8454):515–518CrossRef Lagerstedt C, Fagher B, Olsson CG, Öqvist B, Albrechtsson U (1985) Need for long-term anticoagulant treatment in symptomatic calf-vein thrombosis. Lancet 326(8454):515–518CrossRef
16.
Zurück zum Zitat Research Committee of the British Thoracic Society (1992) Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolism. Lancet 340(8824):873–876 Research Committee of the British Thoracic Society (1992) Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolism. Lancet 340(8824):873–876
17.
Zurück zum Zitat Levine MN, Hirsh J, Gent M, Turpie AG, Weitz J, Ginsberg J, Powers P (1995) Optimal duration of oral anticoagulant therapy: a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis. Thromb Haemost 74(2):606–611PubMed Levine MN, Hirsh J, Gent M, Turpie AG, Weitz J, Ginsberg J, Powers P (1995) Optimal duration of oral anticoagulant therapy: a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis. Thromb Haemost 74(2):606–611PubMed
18.
Zurück zum Zitat Schulman S, Rhedin AS, Lindmarker P, Carlsson A, Lärfars G, Nicol P, Boberg J (1995) A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. N Engl J Med 332(25):1661–1665CrossRefPubMed Schulman S, Rhedin AS, Lindmarker P, Carlsson A, Lärfars G, Nicol P, Boberg J (1995) A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. N Engl J Med 332(25):1661–1665CrossRefPubMed
19.
Zurück zum Zitat Schulman S, Granqvist S, Holmström M, Carlsson A, Lindmarker P, Nicol P, Boberg J (1997) The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. N Engl J Med 336(6):393–398CrossRefPubMed Schulman S, Granqvist S, Holmström M, Carlsson A, Lindmarker P, Nicol P, Boberg J (1997) The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. N Engl J Med 336(6):393–398CrossRefPubMed
20.
Zurück zum Zitat Kearon C, Gent M, Hirsh J, Weitz J, Kovacs MJ, Anderson DR, Julian JA (1999) A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 340(12):901–907CrossRefPubMed Kearon C, Gent M, Hirsh J, Weitz J, Kovacs MJ, Anderson DR, Julian JA (1999) A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 340(12):901–907CrossRefPubMed
21.
Zurück zum Zitat Pinede L, Ninet J, Duhaut P, Chabaud S, Demolombe-Rague S, Durieu I, Boissel J (2001) Comparison of 3 and 6 months of oral anticoagulant therapy after a first episode of proximal deep vein thrombosis or pulmonary embolism and comparison of 6 and 12 weeks of therapy after isolated calf deep vein thrombosis. Circulation 103(20):2453–2460CrossRefPubMed Pinede L, Ninet J, Duhaut P, Chabaud S, Demolombe-Rague S, Durieu I, Boissel J (2001) Comparison of 3 and 6 months of oral anticoagulant therapy after a first episode of proximal deep vein thrombosis or pulmonary embolism and comparison of 6 and 12 weeks of therapy after isolated calf deep vein thrombosis. Circulation 103(20):2453–2460CrossRefPubMed
22.
Zurück zum Zitat Agnelli G, Prandoni P, Santamaria MG, Bagatella P, Iorio A, Bazzan M, Ageno W (2001) Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. N Engl J Med 345(3):165–169CrossRefPubMed Agnelli G, Prandoni P, Santamaria MG, Bagatella P, Iorio A, Bazzan M, Ageno W (2001) Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. N Engl J Med 345(3):165–169CrossRefPubMed
23.
Zurück zum Zitat Ridker PM, Goldhaber SZ, Danielson E, Rosenberg Y, Eby CS, Deitcher SR, Glynn RJ (2003) Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med 348(15):1425–1434CrossRefPubMed Ridker PM, Goldhaber SZ, Danielson E, Rosenberg Y, Eby CS, Deitcher SR, Glynn RJ (2003) Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med 348(15):1425–1434CrossRefPubMed
24.
Zurück zum Zitat Agnelli G, Prandoni P, Becattini C, Silingardi M, Taliani MR, Miccio M, Zonzin P (2003) Extended oral anticoagulant therapy after a first episode of pulmonary embolism. Ann Intern Med 139(1):19–25CrossRefPubMed Agnelli G, Prandoni P, Becattini C, Silingardi M, Taliani MR, Miccio M, Zonzin P (2003) Extended oral anticoagulant therapy after a first episode of pulmonary embolism. Ann Intern Med 139(1):19–25CrossRefPubMed
25.
Zurück zum Zitat Farraj RS (2004) Anticoagulation period in idiopathic venous thromboembolism. How long is enough? Saudi Med J 25(7):848–851PubMed Farraj RS (2004) Anticoagulation period in idiopathic venous thromboembolism. How long is enough? Saudi Med J 25(7):848–851PubMed
26.
Zurück zum Zitat Palareti G, Cosmi B, Legnani C, Tosetto A, Brusi C, Iorio A, Tripodi A (2006) D-dimer testing to determine the duration of anticoagulation therapy. N Engl J Med 355(17):1780–1789CrossRefPubMed Palareti G, Cosmi B, Legnani C, Tosetto A, Brusi C, Iorio A, Tripodi A (2006) D-dimer testing to determine the duration of anticoagulation therapy. N Engl J Med 355(17):1780–1789CrossRefPubMed
27.
Zurück zum Zitat Campbell IA, Bentley DP, Prescott RJ, Routledge PA, Shetty HGM, Williamson IJ (2007) Anticoagulation for three versus six months in patients with deep vein thrombosis or pulmonary embolism, or both: randomised trial. BMJ 334(7595):674CrossRefPubMedPubMedCentral Campbell IA, Bentley DP, Prescott RJ, Routledge PA, Shetty HGM, Williamson IJ (2007) Anticoagulation for three versus six months in patients with deep vein thrombosis or pulmonary embolism, or both: randomised trial. BMJ 334(7595):674CrossRefPubMedPubMedCentral
28.
Zurück zum Zitat Siragusa S, Malato A, Anastasio R, Cigna V, Milio G, Amato C, Mariani G (2008) Residual vein thrombosis to establish duration of anticoagulation after a first episode of deep vein thrombosis: the duration of anticoagulation based on compression ultrasonography (DACUS) study. Blood 112(3):511–515CrossRefPubMed Siragusa S, Malato A, Anastasio R, Cigna V, Milio G, Amato C, Mariani G (2008) Residual vein thrombosis to establish duration of anticoagulation after a first episode of deep vein thrombosis: the duration of anticoagulation based on compression ultrasonography (DACUS) study. Blood 112(3):511–515CrossRefPubMed
29.
Zurück zum Zitat Prandoni P, Prins MH, Lensing AW, Ghirarduzzi A, Ageno W, Imberti D, Agnelli G (2009) Residual thrombosis on ultrasonography to guide the duration of anticoagulation in patients with deep venous thrombosis: a randomized trial. Ann Intern Med 150(9):577–585CrossRefPubMed Prandoni P, Prins MH, Lensing AW, Ghirarduzzi A, Ageno W, Imberti D, Agnelli G (2009) Residual thrombosis on ultrasonography to guide the duration of anticoagulation in patients with deep venous thrombosis: a randomized trial. Ann Intern Med 150(9):577–585CrossRefPubMed
30.
Zurück zum Zitat Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, Goldhaber SZ (2009) Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 361(24):2342–2352CrossRefPubMed Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, Goldhaber SZ (2009) Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 361(24):2342–2352CrossRefPubMed
31.
Zurück zum Zitat Agnelli G, Berkowitz S, Bounameaux H, Büller H, Cohen A, Gallus A, Spadari G (2010) Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 363(26):2499–2510CrossRefPubMed Agnelli G, Berkowitz S, Bounameaux H, Büller H, Cohen A, Gallus A, Spadari G (2010) Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 363(26):2499–2510CrossRefPubMed
32.
Zurück zum Zitat Zhang T, Tsang W, Wijeysundera HC, Ko DT (2013) Reporting and representation of ethnic minorities in cardiovascular trials: a systematic review. Am Heart J 166(1):52–57CrossRefPubMed Zhang T, Tsang W, Wijeysundera HC, Ko DT (2013) Reporting and representation of ethnic minorities in cardiovascular trials: a systematic review. Am Heart J 166(1):52–57CrossRefPubMed
33.
Zurück zum Zitat Jackson LR II, Peterson ED, Okeagu E, Thomas K (2015) Review of race/ethnicity in non vitamin K antagonist oral anticoagulants clinical trials. J Thromb Thrombolysis 39(2):222–227CrossRefPubMed Jackson LR II, Peterson ED, Okeagu E, Thomas K (2015) Review of race/ethnicity in non vitamin K antagonist oral anticoagulants clinical trials. J Thromb Thrombolysis 39(2):222–227CrossRefPubMed
34.
Zurück zum Zitat REGULATION (EU) No 536/2014 of the European Parliament And of the Council of 16 April 2014 on clinical trials on medicinal products for human use, and repealing Directive 2001/20/EC REGULATION (EU) No 536/2014 of the European Parliament And of the Council of 16 April 2014 on clinical trials on medicinal products for human use, and repealing Directive 2001/20/EC
35.
Zurück zum Zitat Sheikh A, Netuveli G, Kai J, Panesar SS (2004) Comparison of reporting of ethnicity in US and European randomised controlled trials. BMJ 329(7457):87–88CrossRefPubMedPubMedCentral Sheikh A, Netuveli G, Kai J, Panesar SS (2004) Comparison of reporting of ethnicity in US and European randomised controlled trials. BMJ 329(7457):87–88CrossRefPubMedPubMedCentral
36.
Zurück zum Zitat Tsang W, Alter DA, Wijeysundera HC, Zhang T, Ko DT (2012) The impact of cardiovascular disease prevalence on women’s enrollment in landmark randomized cardiovascular trials: a systematic review. J Gen Intern Med 27(1):93–98CrossRefPubMed Tsang W, Alter DA, Wijeysundera HC, Zhang T, Ko DT (2012) The impact of cardiovascular disease prevalence on women’s enrollment in landmark randomized cardiovascular trials: a systematic review. J Gen Intern Med 27(1):93–98CrossRefPubMed
37.
Zurück zum Zitat Sardar MR, Badri M, Prince CT, Seltzer J, Kowey PR (2014) Underrepresentation of women, elderly patients, and racial minorities in the randomized trials used for cardiovascular guidelines. JAMA Internal Med 174(11):1868–1870CrossRef Sardar MR, Badri M, Prince CT, Seltzer J, Kowey PR (2014) Underrepresentation of women, elderly patients, and racial minorities in the randomized trials used for cardiovascular guidelines. JAMA Internal Med 174(11):1868–1870CrossRef
38.
Zurück zum Zitat Ford ME, Siminoff LA, Pickelsimer E, Mainous AG, Smith DW, Diaz VA, Tilley BC (2013) Unequal burden of disease, unequal participation in clinical trials: solutions from African American and Latino community members. Health & social work. hlt001 Ford ME, Siminoff LA, Pickelsimer E, Mainous AG, Smith DW, Diaz VA, Tilley BC (2013) Unequal burden of disease, unequal participation in clinical trials: solutions from African American and Latino community members. Health & social work. hlt001
Metadaten
Titel
Review of venous thromboembolism and race: the generalizability of treatment guidelines for high-risk populations
verfasst von
Lonnie T. Sullivan II
Larry R. Jackson II
Kevin L. Thomas
Publikationsdatum
14.03.2016
Verlag
Springer US
Erschienen in
Journal of Thrombosis and Thrombolysis / Ausgabe 2/2016
Print ISSN: 0929-5305
Elektronische ISSN: 1573-742X
DOI
https://doi.org/10.1007/s11239-016-1352-5

Weitere Artikel der Ausgabe 2/2016

Journal of Thrombosis and Thrombolysis 2/2016 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.